Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Metrics to compare | IMRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.7x | −6.0x | −0.5x | |
PEG Ratio | −0.16 | −0.19 | 0.00 | |
Price/Book | 1.5x | 7.1x | 2.6x | |
Price / LTM Sales | - | 13.6x | 3.1x | |
Upside (Analyst Target) | 187.1% | 62.5% | 54.6% | |
Fair Value Upside | Unlock | 7.2% | 7.6% | Unlock |